XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share
6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
The Company’s non-vested restricted stock that was granted prior to March 2015 is considered a participating security since the share-based awards contain a non-forfeitable right to dividends irrespective of whether the awards ultimately vest. Unvested share-based payment awards that contain non-forfeitable rights to dividends are participating securities and are included in the computation of earnings per share pursuant to the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation rights in undistributed earnings.
(in thousands, except per common share data)
Three months ended June 30,
 
Six months ended June 30,
2018
 
2017
 
2018
 
2017
Net income (loss) attributable to The Andersons, Inc.
$
21,529

 
$
(26,653
)
 
$
19,829

 
$
(29,742
)
Less: Distributed and undistributed earnings allocated to nonvested restricted stock

 

 

 

Earnings (losses) available to common shareholders
$
21,529

 
$
(26,653
)
 
$
19,829

 
$
(29,742
)
Earnings per share – basic:
 
 
 
 
 
 
 
Weighted average shares outstanding – basic
28,261

 
28,350

 
28,249

 
28,316

Earnings (losses) per common share – basic
$
0.76

 
$
(0.94
)
 
$
0.70

 
$
(1.05
)
Earnings per share – diluted:
 
 
 
 
 
 
 
Weighted average shares outstanding – basic
28,261

 
28,350

 
28,249

 
28,316

Effect of dilutive awards
128

 

 
187

 

Weighted average shares outstanding – diluted
28,389

 
28,350

 
28,436

 
28,316

Earnings (losses) per common share – diluted
$
0.76

 
$
(0.94
)
 
$
0.70

 
$
(1.05
)

There were 28 thousand and 25 thousand antidilutive stock-based awards outstanding for the three and six months ended June 30, 2018, respectively. All outstanding share awards were antidilutive for the three and six months ended June 30, 2017 as the Company incurred a net loss in these periods.